Novavax is a traditional vaccine that does not transfect cells. It has the potential for a superior safety profile relative to the existing mRNA vaccines. So does COVAXIN.

“The Novavax vaccine was granted emergency use authorization in November in Indonesia, the first country to do so, and was soon followed by the Philippines. The company has also filed with the U.K. and the European Medicines Agency, with plans to apply to the U.S. Food and Drug Administration before the end of this year.

This is good news because this vaccine is a “traditional” vaccine that does not transfect your existing cells, so it “should” have a much better safety profile than any of the three vaccines now available in the US for two major reasons:”

https://stevekirsch.substack.com/p/good-news-who-approves-novavax